Biopharma Sustainability Investor Day

  • Investor perspective: Regulatory developments in the EU, US, UK, China, Japan, …
  • Update on Biopharma investor ESG communications Initiative
  • Key developments and concepts: Double materiality, EU Social Taxonomy, Impact